化学交换饱和转移（CEST）MRI已经被认可为分子成像和定量生物标志物库中的有价值的补充，尤其是用于脑肿瘤的特征分析。越来越多地有兴趣将CEST-MRI用于脑外的应用。然而，它在肿瘤学领域普及的速度远远落后于神经肿瘤领域。CEST-MRI在非神经学应用中的缓慢迁移反映了对躯干成像的成像技术挑战。在这篇综述中，我们讨论了CEST-MRI在乳腺和躯干（即身体成像）肿瘤病情的应用，强调了挑战和可能的解决方案。尽管数据仍然有限，但报道的研究表明CEST信号与重要的组织学标记有关，例如肿瘤分级、受体状态和增殖指数，其中一些常常与预后和治疗反应有关。然而，仍然需要进一步的技术发展，使CEST成为身体成像的可靠临床应用，并确定其作为预测和预后生物标志物的作用 。© 2023 John Wiley & Sons, Ltd.

Chemical exchange saturation transfer (CEST) MRI has gained recognition as a valuable addition to the molecular imaging and quantitative biomarker arsenal, especially for characterization of brain tumors. There is also increasing interest in the use of CEST-MRI for applications beyond the brain. However, its translation to body oncology applications lags behind those in neuro-oncology. The slower migration of CEST-MRI to non-neurologic applications reflects the technical challenges inherent to imaging of the torso. In this review, we discuss the application of CEST-MRI to oncologic conditions of the breast and torso (i.e., body imaging), emphasizing the challenges and potential solutions to address them. While data are still limited, reported studies suggest that CEST signal is associated with important histology markers such as tumor grade, receptor status, and proliferation index, some of which are often associated with prognosis and response to therapy. However, further technical development is still needed to make CEST a reliable clinical application for body imaging and establish its role as a predictive and prognostic biomarker.© 2023 John Wiley & Sons, Ltd.